Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Vir Biotechnology, Inc. (VIR)
USD9.55
+0.06 (+0.58%)
US NASDAQ Healthcare Biotechnology
Address
499 Illinois Street 94158
San Francisco, CA, US
San Francisco, CA, US
CEO
Marianne De Backer
Website
vir.bio
IPO
2019-10-11
CIK 1706431 ISIN US92764N1028
Description
Vir Biotechnology, Inc. operates as an immunology company with commercialized products, dedicated to devising therapeutic solutions for the treatment and prevention of significant infectious diseases. Its pipeline features several key candidates: Sotrovimab (branded as Xevudy, or VIR-7832), a neutralizing monoclonal antibody for both treating and preventing SARS-CoV-2 infection; VIR-2218 and VIR-3434, aimed at hepatitis B virus; VIR-2482, targeting the prevention of influenza A virus; and VIR-1111, designed to prevent human immunodeficiency virus. The firm maintains a robust network of strategic partnerships and collaborations. These include grant support from organizations like the Bill & Melinda Gates Foundation and the National Institutes of Health. It holds option and licensing arrangements with entities such as Brii Biosciences Limited, and a collaboration and license agreement with Alnylam Pharmaceuticals, Inc. Further licensing relationships exist with The Rockefeller University and MedImmune, Inc. Collaborations extend to WuXi Biologics and Glaxo Wellcome UK Ltd., alongside a research agreement with GlaxoSmithKline Biologicals SA. Furthermore, Vir has secured a manufacturing contract with Samsung Biologics Co.,Ltd. for SARS-CoV-2 antibodies and a clinical development partnership with Gilead Sciences, Inc. focused on chronic hepatitis B virus. The company, established in 2016, is headquartered in San Francisco, California.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD9.55
+0.06 (+0.58%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
2M
Beta
1.64
Float Shares
103.15M
Free Float %
64.0%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.86% | -5.78% | -2.21% | +20.49% | +62.70% | +54.06% | +75.28% | -62.37% | -76.25% | -33.74% | -33.74% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (12 ratings, all time)
Buy
Price Targets & DCF
Current price
9.55
Low
18.00
+88.6%
Consensus
21.14
+121.5%
Median
20.00
+109.5%
High
30.00
+214.3%
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 3 | 0 |
| Buy | 7 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | 8 |
21.88
+129.2%
|
| Last Year | 11 |
20.55
+115.3%
|
| All Time | 17 |
22.32
+133.8%
|
Quality scores
Altman Z-Score
1.74
Distress
Piotroski F-Score
3 / 9
Average
MOAT Score
1 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%-7.6% Q1'26: -101.0% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+17.5% Q1'26: +3.4% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-661.6% Q1'26: +457,848.3% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-638.6% Q1'26: +459,241.4% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-89.5% Q1'26: -124.7% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+1.7% ★ Q1'26: +7.2% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.44× Q1'26: -0.17× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 4 Rev. Ana. 5 EPS Ana. |
Dec 2027 4 Rev. Ana. 4 EPS Ana. |
Dec 2028 4 Rev. Ana. 2 EPS Ana. |
Dec 2029 3 Rev. Ana. 1 EPS Ana. |
Dec 2030 3 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
711.0K
est: 9.15M (-92.2%)
|
67.25M
est: 79.35M (-15.3%)
|
1.10B
est: 905.58M (+21.0%)
|
1.62B
est: 1.71B (-5.7%)
|
86.18M
est: 78.88M (+9.3%)
|
74.21M
est: 68.66M (+8.1%)
|
68.56M
est: 20.80M (+229.6%)
|
161.89M
119.04M – 198.95M
+678.4% YoY
|
94.21M
58.00M – 135.84M
-41.8% YoY
|
150.81M
145.15M – 156.46M
+60.1% YoY
|
190.42M
135.52M – 249.79M
+26.3% YoY
|
262.75M
187.00M – 344.68M
+38.0% YoY
|
| EBITDA |
-173.46M
est: -3.83M (-4,432.4%)
|
-291.54M
est: -164.40M (-77.3%)
|
426.56M
est: 374.18M (+14.0%)
|
839.85M
est: 428.75M (+95.9%)
|
-641.64M
est: -32.98M (-1,845.3%)
|
-508.91M
est: -28.71M (-1,672.6%)
|
-426.09M
est: -8.70M (-4,799.5%)
|
-67.70M
-83.19M – -49.78M
-678.4% YoY
|
-39.40M
-56.80M – -24.25M
+41.8% YoY
|
-63.06M
-65.43M – -60.70M
-60.1% YoY
|
-79.63M
-104.45M – -56.67M
-26.3% YoY
|
-109.87M
-144.13M – -78.20M
-38.0% YoY
|
| EBIT |
-177.98M
est: -3.84M (-4,529.4%)
|
-296.98M
est: -254.06M (-16.9%)
|
420.75M
est: -286.07M (+247.1%)
|
833.07M
est: -305.00M (+373.1%)
|
-661.09M
est: -33.13M (-1,895.2%)
|
-523.47M
est: -28.84M (-1,715.1%)
|
-437.77M
est: -8.74M (-4,911.0%)
|
-68.00M
-83.57M – -50.00M
-678.4% YoY
|
-39.58M
-57.06M – -24.36M
+41.8% YoY
|
-63.35M
-65.73M – -60.97M
-60.1% YoY
|
-79.99M
-104.93M – -56.93M
-26.3% YoY
|
-110.37M
-144.79M – -78.55M
-38.0% YoY
|
| Net Income |
-174.68M
est: -250.01M (+30.1%)
|
-298.67M
est: -169.63M (-76.1%)
|
528.58M
est: 341.01M (+55.0%)
|
515.84M
est: 396.47M (+30.1%)
|
-615.06M
est: -483.04M (-27.3%)
|
-521.96M
est: -550.23M (+5.1%)
|
-437.99M
est: -442.72M (+1.1%)
|
-237.77M
-482.04M – -110.92M
+46.3% YoY
|
-377.61M
-408.98M – -273.14M
-58.8% YoY
|
-231.92M
-271.73M – -192.12M
+38.6% YoY
|
-198.64M
-279.15M – -124.19M
+14.4% YoY
|
-163.80M
-230.19M – -102.41M
+17.5% YoY
|
| SGA |
37.60M
est: 1.93M (+1,847.1%)
|
70.94M
est: 48.14M (+47.3%)
|
—
est: 423.35M (-100.0%)
|
—
est: 431.33M (-100.0%)
|
—
est: 21.19M (-100.0%)
|
—
est: 18.44M (-100.0%)
|
92.07M
est: 5.59M (+1,548.2%)
|
43.49M
31.98M – 53.44M
+678.4% YoY
|
25.31M
15.58M – 36.49M
-41.8% YoY
|
40.51M
38.99M – 42.03M
+60.1% YoY
|
51.15M
36.40M – 67.10M
+26.3% YoY
|
70.58M
50.23M – 92.58M
+38.0% YoY
|
| EPS |
-1.62
est: -1.84 (+11.7%)
|
-2.51
est: -2.39 (-5.2%)
|
4.07
est: 2.70 (+50.5%)
|
3.89
est: 4.31 (-9.8%)
|
-4.59
est: -3.58 (-28.4%)
|
-3.83
est: -3.88 (+1.3%)
|
-3.16
est: -3.35 (+5.8%)
|
-1.94
-3.48 – -0.80
+42.2% YoY
|
-2.35
-2.95 – -1.97
-21.4% YoY
|
-1.67
-1.96 – -1.39
+28.8% YoY
|
-1.43
-2.02 – -0.90
+14.4% YoY
|
-1.18
-1.66 – -0.74
+17.5% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-06 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-01 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-393.33M
OE per share TTM
-2.84
Owner's Yield
-25.94%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
27.3%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
52
Total invested
48.70M
Insider transactions (90d)
2
Beneficial owners (>5%)
25
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ARCH Venture Fund IX, L.P. | 28.67M | 23.00% | — | 28.67M | — | 28.67M | PN | Delaware | 2020-07-29 | ↗ |
| 2 | ARCH Venture Partners IX Overage, L.P. | 28.67M | 23.00% | — | 28.67M | — | 28.67M | PN | Delaware | 2020-07-29 | ↗ |
| 3 | ARCH Venture Partners IX, L.P. | 28.67M | 23.00% | — | 28.67M | — | 28.67M | PN | Delaware | 2020-07-29 | ↗ |
| 4 | Clinton Bybee | 28.67M | 23.00% | — | 28.67M | — | 28.67M | IN | United States | 2020-07-29 | ↗ |
| 5 | Keith Crandell | 28.67M | 23.00% | — | 28.67M | — | 28.67M | IN | United States | 2020-07-29 | ↗ |
| 6 | Robert Nelsen | 28.67M | 23.00% | — | 28.67M | — | 28.67M | IN | United States | 2020-07-29 | ↗ |
| 7 | Venture Fund IX Overage, L.P. | 28.67M | 23.00% | — | 28.67M | — | 28.67M | PN | Delaware | 2020-07-29 | ↗ |
| 8 | Venture Partners IX, LLC | 28.67M | 23.00% | — | 28.67M | — | 28.67M | OO | Delaware | 2020-07-29 | ↗ |
| 9 | SB Investment Advisers (UK) Limited | 22.62M | 20.60% | — | 22.62M | — | — | FI | Cayman Islands | 2020-02-14 | ↗ |
| 10 | SVF Victory (Cayman) Limited | 22.62M | 20.60% | — | 22.62M | — | — | FI | Cayman Islands | 2020-02-14 | ↗ |
| 11 | SoftBank Vision Fund (AIV M1) L.P. | 22.62M | 20.60% | — | 22.62M | — | — | PN | Cayman Islands | 2020-02-14 | ↗ |
| 12 | (1) BlackRock, Inc. | 13.38M | 10.10% | 13.15M | — | 13.38M | — | HC | Delaware | 2022-09-08 | ↗ |
| 13 | GlaxoSmithKline plc | 8.55M | 6.50% | 8.55M | — | 8.55M | 8.55M | CO | England and Wales | 2022-02-10 | ↗ |
| 14 | The Vanguard Group - 23-1945930 | 7.33M | 5.60% | — | — | 7.15M | 177.3K | IA | Pennsylvania For | 2022-02-10 | ↗ |
| 15 | Page 2 of 5 Pages | 6.95M | 6.30% | 4.80M | 2.14M | 4.80M | 2.14M | IN | — | 2020-02-14 | ↗ |
| 16 | STATE STREET CORPORATION | 6.91M | 5.14% | — | 6.69M | — | 6.91M | HC | BOSTON, MASSACHUSETTS | 2024-01-24 | ↗ |
| 17 | George A. Scangos | 6.27M | 4.79% | 675.4K | 5.59M | 675.4K | 6.27M | IN | United States of America | 2022-02-14 | ↗ |
| 18 | Fullerton Management Pte Ltd | 5.50M | 5.03% | — | 5.50M | — | 5.50M | HC | Republic of Singapore | 2019-10-25 | ↗ |
| 19 | Temasek Holdings (Private) Limited | 5.50M | 5.03% | — | 5.50M | — | 5.50M | HC | Republic of Singapore | 2019-10-25 | ↗ |
| 20 | Temasek Life Sciences Private Limited | 5.50M | 5.03% | — | 5.50M | — | 5.50M | HC | Republic of Singapore | 2019-10-25 | ↗ |
| 21 | TLS Beta Pte. Ltd. | 5.00M | 4.57% | — | 5.00M | — | 5.00M | CO | Republic of Singapore | 2019-10-25 | ↗ |
| 22 | IN ROW (9) | 5.00M | 3.90% | — | 5.50M | — | 5.50M | CO | Republic of Singapore | 2021-02-11 | ↗ |
| 23 | Alaska Permanent Fund Corporation | 3.89M | 3.06% | 3.83M | 59.7K | 3.83M | — | OO | — | 2021-02-16 | ↗ |
| 24 | V-Sciences | 500.0K | 0.46% | — | 500.0K | — | 500.0K | CO | Republic of Singapore | 2019-10-25 | ↗ |
| 25 | 95-1411037 | 13.00 | 9.00% | 11.41M | — | 11.44M | — | IA | Delaware | 2021-02-16 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
52
-172 vs prev Q
New positions
10
Closed positions
176
Increased
39
Reduced
8
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | — | 930.3K +930.3K (+100.0%) | 5.61B +5.6B (+100.0%) | 0.67% +0.670 pp | 4.02% +4.022 pp | USD6.03 +0.0% | 1 qtrs NEW |
| 2 | BLACKROCK, INC. | 16.33M +362.4K (+2.3%) | 98.47M +7.3M (+8.0%) | 11.75% +0.221 pp | 0.00% +0.000 pp | USD7.45 -19.1% | 6 qtrs — |
| 3 | SB INVESTMENT ADVISERS (UK) LTD | 13.12M -3.6M (-21.4%) | 79.10M -16.2M (-17.0%) | 9.44% -2.609 pp | 0.79% +0.073 pp | USD12.58 -52.1% | 25 qtrs — |
| 4 | ARCH VENTURE MANAGEMENT, LLC | 12.92M +— (+0.0%) | 77.89M +4.1M (+5.6%) | 9.30% -0.032 pp | 11.95% -3.028 pp | USD5.04 +19.6% | 3 qtrs — |
| 5 | VANGUARD GROUP INC | 12.55M -250.4K (-2.0%) | 75.67M +2.6M (+3.5%) | 9.03% -0.212 pp | 0.00% +0.000 pp | USD26.09 -76.9% | 25 qtrs — |
| 6 | GSK PLC | 8.55M +8.6M (+100.0%) | 51.56M +51.6M (+100.0%) | 6.15% +6.155 pp | 6.45% +6.453 pp | USD6.03 +0.0% | 1 qtrs NEW |
| 7 | STATE STREET CORP | 6.23M +988.3K (+18.9%) | 37.56M +7.6M (+25.5%) | 4.48% +0.698 pp | 0.00% +0.000 pp | USD18.19 -66.8% | 25 qtrs — |
| 8 | FMR LLC | 3.16M -478.7K (-13.2%) | 19.05M -1.7M (-8.3%) | 2.27% -0.354 pp | 0.00% 0.000 pp | USD5.94 +1.5% | 17 qtrs — |
| 9 | MORGAN STANLEY | 2.68M -10.0K (-0.4%) | 16.16M +800.4K (+5.2%) | 1.93% -0.014 pp | 0.00% +0.000 pp | USD10.23 -41.1% | 25 qtrs — |
| 10 | DIMENSIONAL FUND ADVISORS LP | 2.54M -442.6K (-14.9%) | 15.29M -1.7M (-10.1%) | 1.83% -0.326 pp | 0.00% 0.000 pp | USD9.79 -38.4% | 22 qtrs — |
| 11 | ORBIMED ADVISORS LLC | 2.38M +— (+0.0%) | 14.36M +761.8K (+5.6%) | 1.71% -0.006 pp | 0.29% -0.026 pp | USD8.52 -29.2% | 9 qtrs — |
| 12 | GEODE CAPITAL MANAGEMENT, LLC | 2.33M +82.0K (+3.6%) | 14.04M +1.2M (+9.5%) | 1.68% +0.053 pp | 0.00% +0.000 pp | USD26.73 -77.4% | 25 qtrs — |
| 13 | GOLDMAN SACHS GROUP INC | 1.57M +47.1K (+3.1%) | 9.46M +771.0K (+8.9%) | 1.13% +0.030 pp | 0.00% +0.000 pp | USD9.96 -39.5% | 25 qtrs — |
| 14 | ABRDN PLC | 1.39M -135.7K (-8.9%) | 8.39M -329.8K (-3.8%) | 1.00% -0.102 pp | 0.01% -0.001 pp | USD6.13 -1.6% | 5 qtrs — |
| 15 | BALYASNY ASSET MANAGEMENT L.P. | 1.37M +1.4M (+100.0%) | 8.25M +8.3M (+100.0%) | 0.99% +0.985 pp | 0.01% +0.011 pp | USD6.03 +0.0% | 1 qtrs NEW |
| 16 | HUDSON BAY CAPITAL MANAGEMENT LP | 1.33M +413.1K (+45.3%) | 7.99M +2.8M (+53.4%) | 0.95% +0.295 pp | 0.03% +0.009 pp | USD7.03 -14.2% | 11 qtrs — |
| 17 | CANDRIAM S.C.A. | 1.03M +1.0M (+100.0%) | 6.22M +6.2M (+100.0%) | 0.74% +0.743 pp | 0.03% +0.031 pp | USD6.03 +0.0% | 1 qtrs NEW |
| 18 | MILLENNIUM MANAGEMENT LLC | 1.00M -393.9K (-28.2%) | 6.05M -1.9M (-24.2%) | 0.72% -0.287 pp | 0.00% -0.001 pp | USD6.54 -7.8% | 23 qtrs — |
| 19 | BANK OF AMERICA CORP /DE/ | 930.9K +529.9K (+132.2%) | 5.61M +3.3M (+145.2%) | 0.67% +0.380 pp | 0.00% +0.000 pp | USD7.05 -14.5% | 25 qtrs — |
| 20 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 904.5K -238.4K (-20.9%) | 5.45M -1.1M (-16.4%) | 0.65% -0.175 pp | 0.00% 0.000 pp | USD20.57 -70.7% | 25 qtrs — |
| 21 | NORTHERN TRUST CORP | 848.5K -58.7K (-6.5%) | 5.12M -63.4K (-1.2%) | 0.61% -0.045 pp | 0.00% +0.000 pp | USD28.06 -78.5% | 25 qtrs — |
| 22 | AMERIPRISE FINANCIAL INC | 731.3K +537.0K (+276.4%) | 4.41M +3.3M (+297.5%) | 0.53% +0.386 pp | 0.00% +0.001 pp | USD10.09 -40.2% | 20 qtrs — |
| 23 | BOXER CAPITAL MANAGEMENT, LLC | 625.0K +625.0K (+100.0%) | 3.77M +3.8M (+100.0%) | 0.45% +0.450 pp | 0.82% +0.825 pp | USD6.03 +0.0% | 1 qtrs NEW |
| 24 | RENAISSANCE TECHNOLOGIES LLC | 614.5K -552.6K (-47.4%) | 3.71M -3.0M (-44.4%) | 0.44% -0.401 pp | 0.01% -0.003 pp | USD18.29 -67.0% | 19 qtrs — |
| 25 | CLARIUS GROUP, LLC | 608.2K -11.1K (-1.8%) | 3.67M +131.2K (+3.7%) | 0.44% -0.010 pp | 0.21% +0.000 pp | USD7.93 -24.0% | 20 qtrs — |
| 26 | HRT FINANCIAL LP | 591.6K +414.9K (+234.7%) | 3.57M +2.6M (+253.5%) | 0.43% +0.298 pp | 0.01% +0.008 pp | USD5.81 +3.8% | 9 qtrs — |
| 27 | TWO SIGMA INVESTMENTS, LP | 589.6K -59.7K (-9.2%) | 3.56M -152.5K (-4.1%) | 0.42% -0.045 pp | 0.01% -0.001 pp | USD7.32 -17.6% | 13 qtrs — |
| 28 | NORDEA INVESTMENT MANAGEMENT AB | 609.7K -104.8K (-14.7%) | 3.55M -384.5K (-9.8%) | 0.44% -0.077 pp | 0.00% 0.000 pp | USD7.91 -23.8% | 18 qtrs — |
| 29 | SCHRODER INVESTMENT MANAGEMENT GROUP | 598.7K +142.4K (+31.2%) | 3.50M +927.3K (+36.1%) | 0.43% +0.101 pp | 0.00% +0.001 pp | USD6.37 -5.3% | 4 qtrs — |
| 30 | TWO SIGMA ADVISERS, LP | 577.7K +73.7K (+14.6%) | 3.48M +605.7K (+21.0%) | 0.42% +0.052 pp | 0.01% +0.001 pp | USD5.91 +2.0% | 7 qtrs — |
| 31 | IKARIAN CAPITAL, LLC | 575.7K -17.7K (-3.0%) | 3.47M +83.4K (+2.5%) | 0.41% -0.014 pp | 0.27% -0.071 pp | USD7.20 -16.3% | 5 qtrs — |
| 32 | NUVEEN, LLC | 565.5K +360.1K (+175.2%) | 3.41M +2.2M (+190.7%) | 0.41% +0.259 pp | 0.00% +0.001 pp | USD6.19 -2.6% | 4 qtrs — |
| 33 | BANK OF NEW YORK MELLON CORP | 545.6K -11.5K (-2.1%) | 3.29M +109.1K (+3.4%) | 0.39% -0.010 pp | 0.00% +0.000 pp | USD26.49 -77.2% | 25 qtrs — |
| 34 | BAKER BROS. ADVISORS LP | 542.5K +— (+0.0%) | 3.27M +173.6K (+5.6%) | 0.39% -0.001 pp | 0.02% -0.003 pp | USD7.34 -17.8% | 5 qtrs — |
| 35 | ENSIGN PEAK ADVISORS, INC | 531.4K -23.6K (-4.2%) | 3.20M +35.6K (+1.1%) | 0.38% -0.018 pp | 0.01% +0.001 pp | USD6.48 -6.9% | 17 qtrs — |
| 36 | ALTA PARTNERS MANAGEMENT COMPANY, L.P. | 509.9K +— (+0.0%) | 3.07M +163.2K (+5.6%) | 0.37% -0.001 pp | 2.97% -1.885 pp | USD7.28 -17.2% | 5 qtrs — |
| 37 | CITADEL ADVISORS LLC | 489.2K -309.8K (-38.8%) | 2.95M -1.6M (-35.3%) | 0.35% -0.225 pp | 0.00% 0.000 pp | USD6.01 +0.3% | 14 qtrs — |
| 38 | SIO CAPITAL MANAGEMENT, LLC | 478.3K +— (+0.0%) | 2.88M +153.1K (+5.6%) | 0.34% -0.001 pp | 0.45% -0.238 pp | USD7.32 -17.6% | 5 qtrs — |
| 39 | PRINCIPAL FINANCIAL GROUP INC | 450.6K -5.1K (-1.1%) | 2.72M +115.0K (+4.4%) | 0.32% -0.005 pp | 0.00% +0.000 pp | USD23.65 -74.5% | 23 qtrs — |
| 40 | JPMORGAN CHASE & CO | 418.6K -30.9K (-6.9%) | 2.52M -42.6K (-1.7%) | 0.30% -0.023 pp | 0.00% +0.000 pp | USD9.70 -37.8% | 25 qtrs — |
| 41 | UBS GROUP AG | 418.0K +203.2K (+94.6%) | 2.52M +1.3M (+105.5%) | 0.30% +0.146 pp | 0.00% +0.000 pp | USD8.28 -27.2% | 25 qtrs — |
| 42 | INVESCO LTD. | 405.7K -12.3K (-2.9%) | 2.45M +59.8K (+2.5%) | 0.29% -0.010 pp | 0.00% +0.000 pp | USD19.61 -69.3% | 23 qtrs — |
| 43 | PANAGORA ASSET MANAGEMENT INC | 371.3K +10.9K (+3.0%) | 2.24M +180.9K (+8.8%) | 0.27% +0.007 pp | 0.01% 0.000 pp | USD5.54 +8.8% | 3 qtrs — |
| 44 | BARCLAYS PLC | 365.8K -184.4K (-33.5%) | 2.21M -1.9M (-46.5%) | 0.26% -0.134 pp | 0.00% -0.001 pp | USD7.74 -22.1% | 16 qtrs — |
| 45 | VOLORIDGE INVESTMENT MANAGEMENT, LLC | 327.4K -189.2K (-36.6%) | 1.97M -975.8K (-33.1%) | 0.24% -0.138 pp | 0.01% -0.003 pp | USD8.61 -30.0% | 10 qtrs — |
| 46 | PUBLIC SECTOR PENSION INVESTMENT BOARD | 326.2K -41.1K (-11.2%) | 1.97M -130.3K (-6.2%) | 0.23% -0.031 pp | 0.01% -0.001 pp | USD12.64 -52.3% | 15 qtrs — |
| 47 | CITIGROUP INC | 311.3K -12.2K (-3.8%) | 1.88M +29.7K (+1.6%) | 0.22% -0.010 pp | 0.00% +0.000 pp | USD7.25 -16.8% | 25 qtrs — |
| 48 | AMERICAN CENTURY COMPANIES INC | 295.4K -626.0 (-0.2%) | 1.78M +91.0K (+5.4%) | 0.21% -0.001 pp | 0.00% +0.000 pp | USD12.96 -53.5% | 15 qtrs — |
| 49 | PRUDENTIAL FINANCIAL INC | 281.5K +29.2K (+11.6%) | 1.70M +256.9K (+17.8%) | 0.20% +0.020 pp | 0.00% +0.000 pp | USD7.90 -23.7% | 20 qtrs — |
| 50 | BNP PARIBAS ARBITRAGE, SNC | 279.7K +260.5K (+1,360.8%) | 1.69M +1.6M (+1,442.6%) | 0.20% +0.188 pp | 0.00% +0.001 pp | USD6.05 -0.3% | 5 qtrs — |
| 51 | JANE STREET GROUP, LLC | 264.0K +191.8K (+265.5%) | 1.59M +1.2M (+285.9%) | 0.19% +0.138 pp | 0.00% +0.000 pp | USD5.94 +1.5% | 23 qtrs — |
| 52 | CI PRIVATE WEALTH, LLC | 260.7K +1.0K (+0.4%) | 1.57M +89.2K (+6.0%) | 0.19% +0.000 pp | 0.00% 0.000 pp | USD20.77 -71.0% | 12 qtrs — |
| 53 | WALLEYE CAPITAL LLC | 256.1K +117.3K (+84.5%) | 1.54M +751.7K (+94.8%) | 0.18% +0.084 pp | 0.00% +0.002 pp | USD6.74 -10.5% | 11 qtrs — |
| 54 | LEGAL & GENERAL GROUP PLC | 240.6K -4.3K (-1.8%) | 1.45M +52.3K (+3.7%) | 0.17% -0.004 pp | 0.00% +0.000 pp | USD25.62 -76.5% | 25 qtrs — |
| 55 | EAGLE HEALTH INVESTMENTS LP | 240.5K +— (+0.0%) | 1.45M +77.0K (+5.6%) | 0.17% -0.001 pp | 0.32% -0.042 pp | USD6.48 -6.9% | 4 qtrs — |
| 56 | TEJARA CAPITAL LTD | 231.2K -25.7K (-10.0%) | 1.39M -72.7K (-5.0%) | 0.17% -0.019 pp | 0.33% -0.437 pp | USD6.49 -7.1% | 5 qtrs — |
| 57 | RHUMBLINE ADVISERS | 208.4K -18.4K (-8.1%) | 1.26M -38.6K (-3.0%) | 0.15% -0.014 pp | 0.00% +0.000 pp | USD25.74 -76.6% | 24 qtrs — |
| 58 | DEUTSCHE BANK AG\ | 206.2K +3.1K (+1.5%) | 1.24M +83.8K (+7.2%) | 0.15% +0.002 pp | 0.00% +0.000 pp | USD10.75 -43.9% | 25 qtrs — |
| 59 | ALLIANZ ASSET MANAGEMENT GMBH | 205.1K -79.1K (-27.8%) | 1.24M -386.0K (-23.8%) | 0.15% -0.058 pp | 0.00% -0.001 pp | USD6.88 -12.4% | 6 qtrs — |
| 60 | POINT72 ASSET MANAGEMENT, L.P. | 195.7K +195.7K (+100.0%) | 1.18M +1.2M (+100.0%) | 0.14% +0.141 pp | 0.00% +0.001 pp | USD6.03 +0.0% | 1 qtrs NEW |
| 61 | WINTON GROUP LTD | 189.3K +131.6K (+227.8%) | 1.14M +811.8K (+246.2%) | 0.14% +0.095 pp | 0.04% +0.027 pp | USD5.93 +1.7% | 22 qtrs — |
| 62 | AQR CAPITAL MANAGEMENT LLC | 186.3K +34.2K (+22.5%) | 1.12M +254.8K (+29.3%) | 0.13% +0.024 pp | 0.00% +0.000 pp | USD6.20 -2.7% | 22 qtrs — |
| 63 | SWISS NATIONAL BANK | 178.0K +7.8K (+4.6%) | 1.07M +101.5K (+10.4%) | 0.13% +0.005 pp | 0.00% +0.000 pp | USD38.24 -84.2% | 19 qtrs — |
| 64 | EXODUSPOINT CAPITAL MANAGEMENT, LP | 177.1K +17.2K (+10.8%) | 1.07M +155.1K (+17.0%) | 0.13% +0.012 pp | 0.01% -0.001 pp | USD5.54 +8.8% | 5 qtrs — |
| 65 | BOOTHBAY FUND MANAGEMENT, LLC | 135.7K -22.4K (-14.2%) | 818.3K -84.6K (-9.4%) | 0.10% -0.017 pp | 0.01% -0.001 pp | USD7.21 -16.4% | 5 qtrs — |
| 66 | RAFFERTY ASSET MANAGEMENT, LLC | 133.8K +19.0K (+16.5%) | 806.6K +151.2K (+23.1%) | 0.10% +0.013 pp | 0.00% +0.001 pp | USD12.94 -53.4% | 21 qtrs — |
| 67 | NEW YORK STATE TEACHERS RETIREMENT SYSTEM | 126.1K +43.3K (+52.3%) | 760.0K +287.0K (+60.7%) | 0.09% +0.031 pp | 0.00% +0.001 pp | USD18.55 -67.5% | 15 qtrs — |
| 68 | UBS ASSET MANAGEMENT AMERICAS INC | 121.1K -22.9K (-15.9%) | 730.1K -91.8K (-11.2%) | 0.09% -0.017 pp | 0.00% +0.000 pp | USD13.72 -56.0% | 23 qtrs — |
| 69 | ALLIANCEBERNSTEIN L.P. | 109.6K +— (+0.0%) | 661.0K +35.1K (+5.6%) | 0.08% 0.000 pp | 0.00% +0.000 pp | USD33.47 -82.0% | 24 qtrs — |
| 70 | MIRAE ASSET GLOBAL ETFS HOLDINGS LTD. | 107.0K +1.0K (+1.0%) | 643.6K +39.0K (+6.5%) | 0.08% +0.001 pp | 0.00% +0.000 pp | USD5.71 +5.6% | 7 qtrs — |
| 71 | WELLS FARGO & COMPANY/MN | 105.4K +30.0K (+39.7%) | 635.6K +204.8K (+47.6%) | 0.08% +0.021 pp | 0.00% +0.000 pp | USD7.45 -19.1% | 25 qtrs — |
| 72 | ACADIAN ASSET MANAGEMENT LLC | 97.9K +3.1K (+3.3%) | 588.0K +49.0K (+9.1%) | 0.07% +0.002 pp | 0.00% +0.000 pp | USD5.72 +5.4% | 4 qtrs — |
| 73 | DIADEMA PARTNERS LP | 89.2K +89.2K (+100.0%) | 537.9K +537.9K (+100.0%) | 0.06% +0.064 pp | 0.09% +0.093 pp | USD6.03 +0.0% | 1 qtrs NEW |
| 74 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | 87.8K -20.5K (-19.0%) | 529.3K -89.2K (-14.4%) | 0.06% -0.015 pp | 0.00% 0.000 pp | USD26.99 -77.7% | 25 qtrs — |
| 75 | QUBE RESEARCH & TECHNOLOGIES LTD | 83.1K -189.1K (-69.5%) | 500.8K -1.1M (-67.8%) | 0.06% -0.137 pp | 0.00% -0.001 pp | USD6.47 -6.8% | 11 qtrs — |
| 76 | PRICE T ROWE ASSOCIATES INC /MD/ | 81.6K +34.5K (+73.1%) | 493.0K +223.0K (+82.6%) | 0.06% +0.025 pp | 0.00% +0.000 pp | USD14.09 -57.2% | 22 qtrs — |
| 77 | CREATIVE PLANNING | 79.7K +27.0K (+51.3%) | 480.6K +179.8K (+59.8%) | 0.06% +0.019 pp | 0.00% +0.000 pp | USD5.85 +3.1% | 9 qtrs — |
| 78 | JAIN GLOBAL LLC | 73.0K +54.6K (+297.2%) | 440.1K +335.2K (+319.5%) | 0.05% +0.039 pp | 0.00% +0.002 pp | USD5.95 +1.3% | 2 qtrs — |
| 79 | TUDOR INVESTMENT CORP ET AL | 68.6K +68.6K (+100.0%) | 413.5K +413.5K (+100.0%) | 0.05% +0.049 pp | 0.00% +0.001 pp | USD6.03 +0.0% | 1 qtrs NEW |
| 80 | LMR PARTNERS LLP | 67.8K -100.0K (-59.6%) | 408.8K -549.3K (-57.3%) | 0.05% -0.072 pp | 0.00% -0.004 pp | USD6.31 -4.4% | 4 qtrs — |
| 81 | COMMONWEALTH EQUITY SERVICES, LLC | 65.7K +— (+0.0%) | 396.4K +21.4K (+5.7%) | 0.05% 0.000 pp | 0.00% +0.000 pp | USD9.98 -39.6% | 8 qtrs — |
| 82 | THRIVENT FINANCIAL FOR LUTHERANS | 65.0K -3.1K (-4.6%) | 392.0K +3.0K (+0.8%) | 0.05% -0.002 pp | 0.00% 0.000 pp | USD23.84 -74.7% | 15 qtrs — |
| 83 | PERSISTENT ASSET PARTNERS LTD | 63.6K +63.6K (+100.0%) | 383.2K +383.2K (+100.0%) | 0.05% +0.046 pp | 0.17% +0.172 pp | USD6.03 +0.0% | 1 qtrs NEW |
| 84 | XTX TOPCO LTD | 60.1K -79.8K (-57.1%) | 362.3K -436.5K (-54.6%) | 0.04% -0.058 pp | 0.01% -0.032 pp | USD5.71 +5.6% | 2 qtrs — |
| 85 | CAMPBELL & CO INVESTMENT ADVISER LLC | 59.8K +59.8K (+100.0%) | 360.5K +360.5K (+100.0%) | 0.04% +0.043 pp | 0.02% +0.017 pp | USD6.03 +0.0% | 1 qtrs NEW |
| 86 | SG AMERICAS SECURITIES, LLC | 59.4K -9.6K (-14.0%) | 358.0K -36.0K (-9.1%) | 0.04% -0.007 pp | 0.00% -0.001 pp | USD6.13 -1.6% | 4 qtrs — |
| 87 | PROFUND ADVISORS LLC | 56.7K +29.0K (+105.0%) | 341.9K +183.9K (+116.5%) | 0.04% +0.021 pp | 0.01% +0.005 pp | USD10.04 -39.9% | 22 qtrs — |
| 88 | QUINN OPPORTUNITY PARTNERS LLC | 51.0K +— (+0.0%) | 307.4K +16.3K (+5.6%) | 0.04% 0.000 pp | 0.01% -0.008 pp | USD7.34 -17.8% | 5 qtrs — |
| 89 | QUADRATURE CAPITAL LTD | 49.8K +49.8K (+100.0%) | 300.3K +300.3K (+100.0%) | 0.04% +0.036 pp | 0.00% +0.003 pp | USD6.03 +0.0% | 1 qtrs NEW |
| 90 | D. E. SHAW & CO., INC. | 49.8K +16.3K (+48.5%) | 300.2K +108.8K (+56.9%) | 0.04% +0.012 pp | 0.00% +0.000 pp | USD8.69 -30.6% | 21 qtrs — |
| 91 | BREVAN HOWARD CAPITAL MANAGEMENT LP | 49.6K +49.6K (+100.0%) | 299.2K +299.2K (+100.0%) | 0.04% +0.036 pp | 0.00% +0.003 pp | USD6.03 +0.0% | 7 qtrs — |
| 92 | SUSQUEHANNA PORTFOLIO STRATEGIES, LLC | 47.4K +— (+0.0%) | 286.0K +15.2K (+5.6%) | 0.03% 0.000 pp | 0.00% +0.000 pp | USD5.04 +19.6% | 3 qtrs — |
| 93 | STATE OF ALASKA, DEPARTMENT OF REVENUE | 47.3K -208.0 (-0.4%) | 285.0K +14.0K (+5.2%) | 0.03% 0.000 pp | 0.00% +0.000 pp | USD12.23 -50.7% | 15 qtrs — |
| 94 | MARTINGALE ASSET MANAGEMENT L P | 44.8K -2.2K (-4.7%) | 270.2K +1.7K (+0.6%) | 0.03% -0.002 pp | 0.01% +0.000 pp | USD16.62 -63.7% | 14 qtrs — |
| 95 | LOUISIANA STATE EMPLOYEES RETIREMENT SYSTEM | 43.3K -100.0 (-0.2%) | 261.1K +13.3K (+5.4%) | 0.03% 0.000 pp | 0.00% +0.000 pp | USD23.44 -74.3% | 16 qtrs — |
| 96 | MITSUBISHI UFJ KOKUSAI ASSET MANAGEMENT CO., LTD. | 43.7K -6.3K (-12.5%) | 259.8K -25.7K (-9.0%) | 0.03% -0.005 pp | 0.00% +0.000 pp | USD12.70 -52.5% | 21 qtrs — |
| 97 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 40.5K +11.5K (+39.7%) | 244.2K +78.6K (+47.5%) | 0.03% +0.008 pp | 0.00% +0.000 pp | USD7.64 -21.1% | 24 qtrs — |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 134 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares Genomics Immunology and Healthcare ETF IDNA | 1.46% | 2.86M | 0.47% |
| 2 | Global X - Genomics & Biotechnology ETF GNOM | 1.02% | 882.6K | 0.50% |
| 3 | Global X - Genomics & Biotechnology UCITS ETF GNOM.L | 1.02% | 531.1K | 0.50% |
| 4 | Virtus Biotech Clinical Trials ETF BBC | 0.71% | 409.8K | 0.65% |
| 5 | Invesco S&P SmallCap Health Care ETF PSCH | 0.53% | 864.2K | 0.29% |
| 6 | Global X - S&P Biotech ETF CURE.AX | 0.46% | 164.4K | 0.45% |
| 7 | State Street SPDR S&P Biotech ETF XBI | 0.46% | 49.39M | 0.35% |
| 8 | Research Affiliates Deletions ETF NIXT | 0.46% | 156.8K | 0.09% |
| 9 | Invesco Russell 2000 Dynamic Multifactor ETF OMFS | 0.17% | 477.9K | 0.39% |
| 10 | iShares Healthcare Innovation UCITS ETF HEAL.L | 0.15% | 1.73M | 0.40% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.33
Bearish
Ratio by volume
0.71
Neutral
Buys
1
Sells
3
Shares acquired
233.5K
Shares disposed
328.1K
Cash buys
—
Cash sales
2.00
Net activity
-94,559
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-01 | SATO VICKI L | Director | S-Sale | D | Common Stock | 22,000 | 10.05 | 221.0K | 1,078,391 | D | ↗ |
| 2026-04-29 | De Backer Marianne | Director / Officer | J-Other | D | Common Stock | 233,532 | 0.00 | — | 714,613 | D | ↗ |
| 2026-04-06 | De Backer Marianne | Director / Officer | S-Sale | D | Common Stock | 72,559 | 9.16 | 664.4K | 948,145 | D | ↗ |
| 2026-04-01 | SATO VICKI L | Director | S-Sale | D | Common Stock | 22,000 | 9.07 | 199.6K | 1,100,391 | D | ↗ |
| 2026-03-23 | Sabatini Brent | Officer | S-Sale | D | Common Stock | 7,711 | 9.12 | 70.3K | 61,902 | D | ↗ |
| 2026-03-20 | O'Byrne Jason | Officer | J-Other | D | Common Stock | 2,500 | 0.00 | — | 160,115 | D | ↗ |
| 2026-03-02 | SATO VICKI L | Director | S-Sale | D | Common Stock | 21,800 | 9.50 | 207.2K | 1,122,591 | D | ↗ |
| 2026-02-25 | de Verneuil Vanina | Officer | S-Sale | D | Common Stock | 13,700 | 9.82 | 134.5K | 112,982 | D | ↗ |
| 2026-02-25 | Eisner Mark | Officer | S-Sale | D | Common Stock | 1,889 | 9.82 | 18.5K | 154,024 | D | ↗ |
| 2026-02-24 | de Verneuil Vanina | Officer | S-Sale | D | Common Stock | 3,117 | 9.53 | 29.7K | 126,682 | D | ↗ |
| 2026-02-24 | Sabatini Brent | Officer | S-Sale | D | Common Stock | 1,430 | 9.53 | 13.6K | 69,613 | D | ↗ |
| 2026-02-24 | SATO VICKI L | Director | S-Sale | D | Common Stock | 200 | 10.26 | 2.1K | 1,144,391 | D | ↗ |
| 2026-02-24 | O'Byrne Jason | Officer | S-Sale | D | Common Stock | 1,634 | 9.53 | 15.6K | 162,615 | D | ↗ |
| 2026-02-24 | Eisner Mark | Officer | S-Sale | D | Common Stock | 1,616 | 9.53 | 15.4K | 155,913 | D | ↗ |
| 2026-02-24 | De Backer Marianne | Director / Officer | S-Sale | D | Common Stock | 14,762 | 9.53 | 140.7K | 1,020,704 | D | ↗ |
| 2026-02-23 | de Verneuil Vanina | Officer | S-Sale | D | Common Stock | 4,445 | 7.45 | 33.1K | 129,799 | D | ↗ |
| 2026-02-23 | Sabatini Brent | Officer | S-Sale | D | Common Stock | 1,829 | 7.45 | 13.6K | 71,043 | D | ↗ |
| 2026-02-23 | O'Byrne Jason | Officer | S-Sale | D | Common Stock | 2,089 | 7.45 | 15.6K | 164,249 | D | ↗ |
| 2026-02-23 | Eisner Mark | Officer | S-Sale | D | Common Stock | 2,089 | 7.45 | 15.6K | 157,529 | D | ↗ |
| 2026-02-23 | De Backer Marianne | Director / Officer | S-Sale | D | Common Stock | 19,039 | 7.45 | 141.9K | 1,035,466 | D | ↗ |
| 2026-02-22 | de Verneuil Vanina | Officer | A-Award | A | Stock Option (Right to Buy) | 110,000 | 7.56 | 831.6K | 110,000 | D | ↗ |
| 2026-02-22 | Sabatini Brent | Officer | A-Award | A | Common Stock | 25,000 | 0.00 | — | 72,872 | D | ↗ |
| 2026-02-22 | O'Byrne Jason | Officer | A-Award | A | Common Stock | 55,000 | 0.00 | — | 166,338 | D | ↗ |
| 2026-02-22 | Eisner Mark | Officer | A-Award | A | Stock Option (Right to Buy) | 110,000 | 7.56 | 831.6K | 110,000 | D | ↗ |
| 2026-02-22 | De Backer Marianne | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 570,000 | 7.56 | 4.31M | 570,000 | D | ↗ |
| 2026-02-13 | Sabatini Brent | Officer | S-Sale | D | Common Stock | 1,530 | 7.79 | 11.9K | 47,872 | D | ↗ |
| 2026-02-02 | SATO VICKI L | Director | S-Sale | D | Common Stock | 22,000 | 7.71 | 169.7K | 1,144,391 | D | ↗ |
| 2026-01-02 | SATO VICKI L | Director | S-Sale | D | Common Stock | 22,000 | 5.93 | 130.4K | 1,166,391 | D | ↗ |
| 2025-12-01 | SVF Endurance (Cayman) Ltd | 10% Owner | S-Sale | D | Common Stock | 191,854 | 5.98 | 1.15M | 13,728,924 | I | ↗ |
| 2025-12-01 | SATO VICKI L | Director | S-Sale | D | Common Stock | 22,000 | 6.00 | 132.1K | 1,188,391 | D | ↗ |
| 2025-11-28 | SVF Endurance (Cayman) Ltd | 10% Owner | S-Sale | D | Common Stock | 61,493 | 6.44 | 396.0K | 13,920,778 | I | ↗ |
| 2025-11-26 | SVF Endurance (Cayman) Ltd | 10% Owner | S-Sale | D | Common Stock | 127,938 | 6.39 | 817.7K | 13,982,271 | I | ↗ |
| 2025-11-25 | SVF Endurance (Cayman) Ltd | 10% Owner | S-Sale | D | Common Stock | 235,971 | 6.38 | 1.51M | 14,110,209 | I | ↗ |
| 2025-11-24 | SVF Endurance (Cayman) Ltd | 10% Owner | S-Sale | D | Common Stock | 227,803 | 6.15 | 1.40M | 14,346,180 | I | ↗ |
| 2025-11-17 | O'Byrne Jason | Officer | S-Sale | D | Common Stock | 6,799 | 5.56 | 37.8K | 110,701 | D | ↗ |
| 2025-11-05 | de Verneuil Vanina | Officer | S-Sale | D | Common Stock | 2,385 | 5.16 | 12.3K | 78,210 | D | ↗ |
| 2025-11-03 | de Verneuil Vanina | Officer | S-Sale | D | Common Stock | 1,365 | 5.86 | 8.0K | 80,595 | D | ↗ |
| 2025-11-03 | SATO VICKI L | Director | S-Sale | D | Common Stock | 22,000 | 5.64 | 124.0K | 1,210,391 | D | ↗ |
| 2025-10-29 | SVF Endurance (Cayman) Ltd | 10% Owner | S-Sale | D | Common Stock | 100 | 6.49 | 649.00 | 14,573,983 | I | ↗ |
| 2025-10-28 | SVF Endurance (Cayman) Ltd | 10% Owner | S-Sale | D | Common Stock | 24,453 | 6.50 | 159.0K | 14,574,083 | I | ↗ |
| 2025-10-27 | SVF Endurance (Cayman) Ltd | 10% Owner | S-Sale | D | Common Stock | 66,403 | 6.05 | 401.6K | 14,598,536 | I | ↗ |
| 2025-10-24 | SVF Endurance (Cayman) Ltd | 10% Owner | S-Sale | D | Common Stock | 46,696 | 5.96 | 278.3K | 14,664,939 | I | ↗ |
| 2025-10-23 | SVF Endurance (Cayman) Ltd | 10% Owner | S-Sale | D | Common Stock | 154,383 | 5.99 | 924.7K | 14,711,635 | I | ↗ |
| 2025-10-22 | SVF Endurance (Cayman) Ltd | 10% Owner | S-Sale | D | Common Stock | 144,266 | 6.15 | 887.7K | 14,866,018 | I | ↗ |
| 2025-10-21 | SVF Endurance (Cayman) Ltd | 10% Owner | S-Sale | D | Common Stock | 109,675 | 6.30 | 691.0K | 15,010,284 | I | ↗ |
| 2025-10-20 | SVF Endurance (Cayman) Ltd | 10% Owner | S-Sale | D | Common Stock | 220,535 | 6.20 | 1.37M | 15,119,959 | I | ↗ |
| 2025-10-16 | SVF Endurance (Cayman) Ltd | 10% Owner | S-Sale | D | Common Stock | 12,844 | 6.10 | 78.4K | 15,340,494 | I | ↗ |
| 2025-10-15 | SVF Endurance (Cayman) Ltd | 10% Owner | S-Sale | D | Common Stock | 16,671 | 6.07 | 101.2K | 15,353,338 | I | ↗ |
| 2025-10-10 | SVF Endurance (Cayman) Ltd | 10% Owner | S-Sale | D | Common Stock | 2,300 | 6.08 | 14.0K | 15,370,009 | I | ↗ |
| 2025-10-09 | SVF Endurance (Cayman) Ltd | 10% Owner | S-Sale | D | Common Stock | 249,060 | 6.14 | 1.53M | 15,372,309 | I | ↗ |
| 2025-10-08 | SVF Endurance (Cayman) Ltd | 10% Owner | S-Sale | D | Common Stock | 466,242 | 6.05 | 2.82M | 15,621,369 | I | ↗ |
| 2025-10-07 | SVF Endurance (Cayman) Ltd | 10% Owner | S-Sale | D | Common Stock | 72,133 | 5.60 | 404.2K | 16,087,611 | I | ↗ |
| 2025-10-06 | SVF Endurance (Cayman) Ltd | 10% Owner | S-Sale | D | Common Stock | 73,955 | 5.69 | 420.6K | 16,159,744 | I | ↗ |
| 2025-10-03 | SVF Endurance (Cayman) Ltd | 10% Owner | S-Sale | D | Common Stock | 450,342 | 5.56 | 2.50M | 16,233,699 | I | ↗ |
| 2025-10-01 | SATO VICKI L | Director | S-Sale | D | Common Stock | 22,000 | 5.84 | 128.4K | 1,232,391 | D | ↗ |
| 2025-09-02 | SATO VICKI L | Director | S-Sale | D | Common Stock | 22,000 | 4.99 | 109.8K | 1,254,391 | D | ↗ |
| 2025-08-01 | SATO VICKI L | Director | S-Sale | D | Common Stock | 22,000 | 4.99 | 109.7K | 1,276,391 | D | ↗ |
| 2025-07-17 | Eisner Mark | Officer | S-Sale | D | Common Stock | 3,586 | 5.47 | 19.6K | 104,618 | D | ↗ |
| 2025-07-15 | Eisner Mark | Officer | S-Sale | D | Common Stock | 6,796 | 5.47 | 37.2K | 108,204 | D | ↗ |
| 2025-07-01 | SATO VICKI L | Director | S-Sale | D | Common Stock | 22,000 | 5.10 | 112.2K | 1,298,391 | D | ↗ |
| 2025-06-09 | MORE ROBERT J | Director | J-Other | A | Common Stock | 14,027 | 0.00 | — | 509,917 | I | ↗ |
| 2025-06-06 | BISCHOFBERGER NORBERT W | Director | J-Other | A | Common Stock | 10,667 | 0.00 | — | 10,667 | I | ↗ |
| 2025-06-02 | Napolitano Janet | Director | S-Sale | D | Common Stock | 3,200 | 5.05 | 16.1K | 16,416 | D | ↗ |
| 2025-05-30 | Sigal Charles Elliott | Director | A-Award | A | Stock Option (Right to Buy) | 16,000 | 4.94 | 79.0K | 16,000 | D | ↗ |
| 2025-05-30 | SATO VICKI L | Director | A-Award | A | Stock Option (Right to Buy) | 16,000 | 4.94 | 79.0K | 16,000 | D | ↗ |
| 2025-05-30 | Ramasastry Saira | Director | A-Award | A | Stock Option (Right to Buy) | 16,000 | 4.94 | 79.0K | 16,000 | D | ↗ |
| 2025-05-30 | Napolitano Janet | Director | A-Award | A | Stock Option (Right to Buy) | 16,000 | 4.94 | 79.0K | 16,000 | D | ↗ |
| 2025-05-30 | MORE ROBERT J | Director | A-Award | A | Stock Option (Right to Buy) | 16,000 | 4.94 | 79.0K | 16,000 | D | ↗ |
| 2025-05-30 | Hatfield Jeffrey S. | Director | A-Award | A | Stock Option (Right to Buy) | 16,000 | 4.94 | 79.0K | 16,000 | D | ↗ |
| 2025-05-30 | Farid Ramy | Director | A-Award | A | Stock Option (Right to Buy) | 16,000 | 4.94 | 79.0K | 16,000 | D | ↗ |
| 2025-05-30 | BISCHOFBERGER NORBERT W | Director | A-Award | A | Stock Option (Right to Buy) | 16,000 | 4.94 | 79.0K | 16,000 | D | ↗ |
| 2025-04-03 | De Backer Marianne | Director / Officer | S-Sale | D | Common Stock | 79,712 | 5.95 | 474.2K | 769,505 | D | ↗ |
| 2025-02-26 | de Verneuil Vanina | Officer | S-Sale | D | Common Stock | 7,373 | 9.14 | 67.4K | 79,460 | D | ↗ |
| 2025-02-24 | de Verneuil Vanina | Officer | S-Sale | D | Common Stock | 5,140 | 9.45 | 48.6K | 86,833 | D | ↗ |
| 2025-02-24 | Sabatini Brent | Officer | S-Sale | D | Common Stock | 1,562 | 9.45 | 14.8K | 46,627 | D | ↗ |
| 2025-02-24 | SCANGOS GEORGE A | Director | S-Sale | D | Common Stock | 10,056 | 9.45 | 95.1K | 698,239 | D | ↗ |
| 2025-02-24 | HANLY ANN M. | Officer | S-Sale | D | Common Stock | 14,168 | 9.45 | 133.9K | 117,901 | D | ↗ |
| 2025-02-24 | De Backer Marianne | Director / Officer | S-Sale | D | Common Stock | 16,122 | 9.45 | 152.4K | 849,217 | D | ↗ |
| 2025-02-22 | de Verneuil Vanina | Officer | A-Award | A | Stock Option (Right to Buy) | 70,000 | 9.57 | 669.9K | 70,000 | D | ↗ |
| 2025-02-22 | Sabatini Brent | Officer | A-Award | A | Stock Option (Right to Buy) | 40,000 | 9.57 | 382.8K | 40,000 | D | ↗ |
| 2025-02-22 | O'Byrne Jason | Officer | A-Award | A | Stock Option (Right to Buy) | 80,000 | 9.57 | 765.6K | 80,000 | D | ↗ |
| 2025-02-22 | Eisner Mark | Officer | A-Award | A | Stock Option (Right to Buy) | 80,000 | 9.57 | 765.6K | 80,000 | D | ↗ |
| 2025-02-22 | De Backer Marianne | Director / Officer | A-Award | A | Common Stock | 240,000 | 0.00 | — | 865,339 | D | ↗ |
| 2025-02-18 | SCANGOS GEORGE A | Director | S-Sale | D | Common Stock | 10,964 | 9.81 | 107.6K | 708,295 | D | ↗ |
| 2025-02-13 | Sabatini Brent | Officer | S-Sale | D | Common Stock | 1,562 | 9.15 | 14.3K | 28,189 | D | ↗ |
| 2025-01-08 | SATO VICKI L | Director | S-Sale | D | Common Stock | 10,960 | 12.52 | 137.2K | 1,312,391 | D | ↗ |
| 2024-12-02 | de Verneuil Vanina | Officer | S-Sale | D | Common Stock | 76 | 8.22 | 624.73 | 56,973 | D | ↗ |
| 2024-11-15 | O'Byrne Jason | Officer | A-Award | A | Stock Option (Right to Buy) | 150,000 | 8.64 | 1.30M | 150,000 | D | ↗ |
| 2024-11-06 | de Verneuil Vanina | Officer | S-Sale | D | Common Stock | 4,397 | 10.11 | 44.5K | 56,973 | D | ↗ |
| 2024-11-05 | de Verneuil Vanina | Officer | S-Sale | D | Common Stock | 2,347 | 9.47 | 22.2K | 61,370 | D | ↗ |
| 2024-11-01 | de Verneuil Vanina | Officer | S-Sale | D | Common Stock | 1,403 | 7.20 | 10.1K | 63,717 | D | ↗ |
| 2024-10-23 | SCANGOS GEORGE A | Director | J-Other | D | Common Stock | 598,270 | 0.00 | — | 1,151,730 | I | ↗ |
| 2024-10-02 | O'Byrne Jason | Officer | — | — | Common Stock | 0 | 0.00 | — | 0 | D | ↗ |
| 2024-10-01 | de Verneuil Vanina | Officer | — | — | Stock Option (Right to Buy) | 58,000 | 39.31 | 2.28M | 0 | D | ↗ |
| 2024-10-01 | Sabatini Brent | Officer | — | — | Stock Option (Right to Buy) | 30,000 | 10.11 | 303.3K | 0 | D | ↗ |
| 2024-09-09 | Napolitano Janet | Director | S-Sale | D | Common Stock | 12,190 | 7.80 | 95.0K | 11,616 | — | ↗ |
| 2024-07-15 | Eisner Mark | Officer | A-Award | A | Stock Option (Right to Buy) | 150,000 | 9.37 | 1.41M | 150,000 | — | ↗ |
| 2024-06-12 | De Backer Marianne | Director / Officer | J-Other | D | Common Stock | 53,118 | 0.00 | — | 625,339 | — | ↗ |
| 2024-06-11 | Ramasastry Saira | Director | S-Sale | D | Common Stock | 4,000 | 10.95 | 43.8K | 14,619 | — | ↗ |
| 2024-06-03 | Eisner Mark | Officer | — | D | Common Stock | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-05-30 | Sigal Charles Elliott | Director | A-Award | A | Common Stock | 8,000 | 0.00 | — | 23,806 | — | ↗ |
| 2024-05-30 | SCANGOS GEORGE A | Director | A-Award | A | Stock Option (Right to Buy) | 16,000 | 10.39 | 166.2K | 16,000 | — | ↗ |
| 2024-05-30 | SATO VICKI L | Director | A-Award | A | Stock Option (Right to Buy) | 16,000 | 10.39 | 166.2K | 16,000 | — | ↗ |
| 2024-05-30 | Ramasastry Saira | Director | A-Award | A | Common Stock | 8,000 | 0.00 | — | 18,619 | — | ↗ |
| 2024-05-30 | Napolitano Janet | Director | A-Award | A | Stock Option (Right to Buy) | 16,000 | 10.39 | 166.2K | 16,000 | — | ↗ |
| 2024-05-30 | NELSEN ROBERT | Director | A-Award | A | Stock Option (Right to Buy) | 16,000 | 10.39 | 166.2K | 16,000 | — | ↗ |
| 2024-05-30 | MORE ROBERT J | Director | A-Award | A | Stock Option (Right to Buy) | 16,000 | 10.39 | 166.2K | 16,000 | — | ↗ |
| 2024-05-30 | Hatfield Jeffrey S. | Director | A-Award | A | Stock Option (Right to Buy) | 16,000 | 10.39 | 166.2K | 16,000 | — | ↗ |
| 2024-05-29 | Farid Ramy | Director | A-Award | A | Stock Option (Right to Buy) | 16,000 | 10.10 | 161.6K | 16,000 | — | ↗ |
| 2024-05-29 | BISCHOFBERGER NORBERT W | Director | A-Award | A | Stock Option (Right to Buy) | 16,000 | 10.10 | 161.6K | 16,000 | — | ↗ |
| 2024-04-03 | De Backer Marianne | Director / Officer | S-Sale | D | Common Stock | 72,995 | 9.46 | 690.4K | 678,457 | — | ↗ |
| 2024-04-01 | HANLY ANN M. | Officer | S-Sale | D | Common Stock | 2,711 | 10.05 | 27.3K | 132,069 | — | ↗ |
| 2024-03-27 | Lee Sung | Officer | S-Sale | D | Common Stock | 6,008 | 9.89 | 59.4K | 100,492 | — | ↗ |
| 2024-02-26 | SCANGOS GEORGE A | Director | S-Sale | D | Common Stock | 17,722 | 11.65 | 206.5K | 112,989 | — | ↗ |
| 2024-02-22 | SCANGOS GEORGE A | Director | S-Sale | D | Common Stock | 10,028 | 10.05 | 100.7K | 130,711 | — | ↗ |
| 2024-02-22 | Pang Phillip | Officer | S-Sale | D | Common Stock | 14,568 | 10.05 | 146.3K | 250,111 | — | ↗ |
| 2024-02-22 | Lee Sung | Officer | A-Award | A | Common Stock | 40,000 | 0.00 | — | 106,500 | — | ↗ |
| 2024-02-22 | HANLY ANN M. | Officer | A-Award | A | Stock Option (Right to Buy) | 65,000 | 10.11 | 657.2K | 65,000 | — | ↗ |
| 2024-02-22 | De Backer Marianne | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 350,000 | 10.11 | 3.54M | 350,000 | — | ↗ |
| 2024-02-20 | SCANGOS GEORGE A | Director | S-Sale | D | Common Stock | 16,872 | 10.22 | 172.4K | 140,739 | — | ↗ |
| 2024-02-16 | SCANGOS GEORGE A | Director | S-Sale | D | Common Stock | 10,878 | 10.24 | 111.4K | 157,611 | — | ↗ |
| 2024-02-16 | Pang Phillip | Officer | S-Sale | D | Common Stock | 3,321 | 10.24 | 34.0K | 264,679 | — | ↗ |
| 2024-01-02 | Pang Phillip | Officer | M-Exempt | A | Common Stock | 18,833 | 0.86 | 16.1K | 206,833 | — | ↗ |
| 2023-10-19 | MORE ROBERT J | Director | J-Other | A | Common Stock | 6,405 | 0.00 | — | 495,890 | — | ↗ |
| 2023-10-17 | SCANGOS GEORGE A | Director | J-Other | A | Common Stock | 1,750,000 | 0.00 | — | 1,750,000 | — | ↗ |
| 2023-09-15 | SCANGOS GEORGE A | Director | J-Other | A | Common Stock | 1,750,000 | 0.00 | — | 1,918,489 | — | ↗ |
| 2023-06-30 | SVF Endurance (Cayman) Ltd | 10% Owner | S-Sale | D | Common Stock | 700 | 25.11 | 17.6K | 16,684,041 | — | ↗ |
| 2023-06-30 | SATO VICKI L | Director | S-Sale | D | Common Stock | 18,000 | 24.66 | 443.9K | 1,315,351 | — | ↗ |
| 2023-06-29 | SVF Endurance (Cayman) Ltd | 10% Owner | S-Sale | D | Common Stock | 89,942 | 25.18 | 2.26M | 16,684,741 | — | ↗ |
| 2023-06-28 | SVF Endurance (Cayman) Ltd | 10% Owner | S-Sale | D | Common Stock | 7,010 | 25.10 | 175.9K | 16,774,683 | — | ↗ |
| 2023-06-20 | SVF Endurance (Cayman) Ltd | 10% Owner | S-Sale | D | Common Stock | 9,902 | 25.18 | 249.3K | 16,781,693 | — | ↗ |
| 2023-06-16 | SVF Endurance (Cayman) Ltd | 10% Owner | S-Sale | D | Common Stock | 111,107 | 25.33 | 2.81M | 16,808,632 | — | ↗ |
| 2023-06-15 | SVF Endurance (Cayman) Ltd | 10% Owner | S-Sale | D | Common Stock | 52,765 | 25.85 | 1.36M | 16,922,156 | — | ↗ |
| 2023-06-14 | SVF Endurance (Cayman) Ltd | 10% Owner | S-Sale | D | Common Stock | 20,967 | 25.92 | 543.5K | 17,011,202 | — | ↗ |
| 2023-06-13 | SVF Endurance (Cayman) Ltd | 10% Owner | S-Sale | D | Common Stock | 36,547 | 26.81 | 979.7K | 17,102,476 | — | ↗ |
| 2023-06-07 | Pang Phillip | Officer | M-Exempt | D | Stock Option (Right to Buy) | 5,000 | 1.53 | 7.7K | 47,591 | — | ↗ |
| 2023-06-05 | SVF Endurance (Cayman) Ltd | 10% Owner | S-Sale | D | Common Stock | 5,197 | 27.32 | 142.0K | 17,139,023 | — | ↗ |
| 2023-06-02 | SVF Endurance (Cayman) Ltd | 10% Owner | S-Sale | D | Common Stock | 34,365 | 27.32 | 938.7K | 17,144,220 | — | ↗ |
| 2023-06-01 | Rice Steven J. | Officer | S-Sale | D | Common Stock | 2,500 | 25.67 | 64.2K | 106,840 | — | ↗ |
| 2023-06-01 | Ramasastry Saira | Director | S-Sale | D | Common Stock | 3,500 | 25.67 | 89.8K | 10,619 | — | ↗ |
| 2023-05-24 | SVF Endurance (Cayman) Ltd | 10% Owner | S-Sale | D | Common Stock | 2,323 | 27.12 | 63.0K | 17,178,585 | — | ↗ |
| 2023-05-23 | SVF Endurance (Cayman) Ltd | 10% Owner | S-Sale | D | Common Stock | 2,317 | 25.84 | 59.9K | 17,450,719 | — | ↗ |
| 2023-05-22 | Sigal Charles Elliott | Director | A-Award | A | Stock Option (Right to Buy) | 12,054 | 25.74 | 310.3K | 12,054 | — | ↗ |
| 2023-05-22 | SVF Endurance (Cayman) Ltd | 10% Owner | S-Sale | D | Common Stock | 91,896 | 25.72 | 2.36M | 17,453,036 | — | ↗ |
| 2023-05-22 | SHARP PHILLIP A | Director | A-Award | A | Stock Option (Right to Buy) | 12,054 | 25.74 | 310.3K | 12,054 | — | ↗ |
| 2023-05-22 | SATO VICKI L | Director | A-Award | A | Stock Option (Right to Buy) | 12,054 | 25.74 | 310.3K | 12,054 | — | ↗ |
| 2023-05-22 | Ramasastry Saira | Director | A-Award | A | Stock Option (Right to Buy) | 12,054 | 25.74 | 310.3K | 12,054 | — | ↗ |
| 2023-05-22 | PEREZ ROBERT J | Director | A-Award | A | Stock Option (Right to Buy) | 12,054 | 25.74 | 310.3K | 12,054 | — | ↗ |
| 2023-05-22 | Napolitano Janet | Director | A-Award | A | Stock Option (Right to Buy) | 12,054 | 25.74 | 310.3K | 12,054 | — | ↗ |
| 2023-05-22 | NELSEN ROBERT | Director / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 12,054 | 25.74 | 310.3K | 12,054 | — | ↗ |
| 2023-05-22 | MORE ROBERT J | Director | A-Award | A | Stock Option (Right to Buy) | 12,054 | 25.74 | 310.3K | 12,054 | — | ↗ |
| 2023-05-22 | Hatfield Jeffrey S. | Director | A-Award | A | Common Stock | 6,027 | 0.00 | — | 15,806 | — | ↗ |
| 2023-05-19 | SVF Endurance (Cayman) Ltd | 10% Owner | S-Sale | D | Common Stock | 91,651 | 25.38 | 2.33M | 17,544,932 | — | ↗ |
| 2023-05-05 | SVF Endurance (Cayman) Ltd | 10% Owner | S-Sale | D | Common Stock | 136 | 25.10 | 3.4K | 17,636,583 | — | ↗ |
| 2023-05-04 | SVF Endurance (Cayman) Ltd | 10% Owner | S-Sale | D | Common Stock | 114,332 | 25.55 | 2.92M | 17,636,719 | — | ↗ |
| 2023-05-03 | SVF Endurance (Cayman) Ltd | 10% Owner | S-Sale | D | Common Stock | 83,674 | 25.51 | 2.13M | 17,751,051 | — | ↗ |
| 2023-05-01 | SVF Endurance (Cayman) Ltd | 10% Owner | S-Sale | D | Common Stock | 3,075 | 25.30 | 77.8K | 17,834,725 | — | ↗ |
| 2023-04-25 | SVF Endurance (Cayman) Ltd | 10% Owner | S-Sale | D | Common Stock | 961 | 25.30 | 24.3K | 17,837,800 | — | ↗ |
| 2023-04-24 | SVF Endurance (Cayman) Ltd | 10% Owner | S-Sale | D | Common Stock | 66,038 | 25.42 | 1.68M | 17,838,761 | — | ↗ |
| 2023-04-21 | SVF Endurance (Cayman) Ltd | 10% Owner | S-Sale | D | Common Stock | 289,485 | 25.76 | 7.46M | 17,920,707 | — | ↗ |
| 2023-04-20 | SVF Endurance (Cayman) Ltd | 10% Owner | S-Sale | D | Common Stock | 6,590 | 25.06 | 165.1K | 18,210,192 | — | ↗ |
| 2023-04-19 | SVF Endurance (Cayman) Ltd | 10% Owner | S-Sale | D | Common Stock | 76,114 | 25.12 | 1.91M | 18,216,782 | — | ↗ |
| 2023-04-18 | SVF Endurance (Cayman) Ltd | 10% Owner | S-Sale | D | Common Stock | 6,953 | 25.12 | 174.7K | 18,292,896 | — | ↗ |
| 2023-04-17 | SVF Endurance (Cayman) Ltd | 10% Owner | S-Sale | D | Common Stock | 10,524 | 25.06 | 263.7K | 18,299,849 | — | ↗ |
| 2023-04-14 | SVF Endurance (Cayman) Ltd | 10% Owner | S-Sale | D | Common Stock | 9,565 | 25.11 | 240.2K | 18,310,373 | — | ↗ |
| 2023-04-03 | De Backer Marianne | Officer | A-Award | A | Common Stock | 576,452 | 0.00 | — | 576,452 | — | ↗ |
| 2023-03-30 | HANLY ANN M. | Officer | S-Sale | D | Common Stock | 2,627 | 22.77 | 59.8K | 114,576 | — | ↗ |
| 2023-03-27 | Lee Sung | Officer | A-Award | A | Stock Option (Right to Buy) | 133,000 | 23.01 | 3.06M | 133,000 | — | ↗ |
| 2023-03-08 | SATO VICKI L | Director | S-Sale | D | Common Stock | 17,935 | 22.59 | 405.1K | 1,327,324 | — | ↗ |
| 2023-03-03 | Friedl-Naderer Johanna | Officer | S-Sale | D | Common Stock | 1,482 | 22.82 | 33.8K | 148,518 | — | ↗ |
| 2023-03-01 | Sigal Charles Elliott | Director | P-Purchase | A | Common Stock | 2,500 | 22.73 | 56.8K | 10,000 | — | ↗ |
| 2023-02-27 | Pang Phillip | Officer | S-Sale | D | Common Stock | 8,920 | 23.00 | 205.2K | 189,400 | — | ↗ |
| 2023-02-24 | SCANGOS GEORGE A | Director / Officer | S-Sale | D | Common Stock | 4,239 | 22.74 | 96.4K | 179,369 | — | ↗ |
| 2023-02-23 | SCANGOS GEORGE A | Director / Officer | S-Sale | D | Common Stock | 12,631 | 25.97 | 328.1K | 183,608 | — | ↗ |
| 2023-02-23 | Rice Steven J. | Officer | S-Sale | D | Common Stock | 1,795 | 25.97 | 46.6K | 108,414 | — | ↗ |
| 2023-02-23 | Pang Phillip | Officer | S-Sale | D | Common Stock | 2,878 | 25.97 | 74.8K | 198,320 | — | ↗ |
| 2023-02-23 | Horn Howard | Officer | S-Sale | D | Common Stock | 2,248 | 25.97 | 58.4K | 230,712 | — | ↗ |
| 2023-02-23 | HANLY ANN M. | Officer | S-Sale | D | Common Stock | 2,302 | 25.97 | 59.8K | 117,203 | — | ↗ |
| 2023-02-22 | Rice Steven J. | Officer | A-Award | A | Common Stock | 73,000 | 0.00 | — | 110,209 | — | ↗ |
| 2023-02-22 | Pang Phillip | Officer | A-Award | A | Stock Option (Right to Buy) | 70,000 | 27.01 | 1.89M | 70,000 | — | ↗ |
| 2023-02-22 | HANLY ANN M. | Officer | A-Award | A | Stock Option (Right to Buy) | 55,000 | 27.01 | 1.49M | 55,000 | — | ↗ |
| 2023-02-22 | Friedl-Naderer Johanna | Officer | A-Award | A | Stock Option (Right to Buy) | 70,000 | 27.01 | 1.89M | 70,000 | — | ↗ |
| 2023-02-21 | SVF Endurance (Cayman) Ltd | 10% Owner | S-Sale | D | Common Stock | 242 | 26.95 | 6.5K | 18,394,173 | — | ↗ |
| 2023-02-21 | SCANGOS GEORGE A | Director / Officer | S-Sale | D | Common Stock | 6,474 | 28.80 | 186.5K | 196,239 | — | ↗ |
| 2023-02-17 | SCANGOS GEORGE A | Director / Officer | S-Sale | D | Common Stock | 9,894 | 25.29 | 250.2K | 214,095 | — | ↗ |
| 2023-02-17 | Rice Steven J. | Officer | S-Sale | D | Common Stock | 1,981 | 25.29 | 50.1K | 37,209 | — | ↗ |
| 2023-02-17 | Pang Phillip | Officer | S-Sale | D | Common Stock | 2,802 | 25.29 | 70.9K | 141,198 | — | ↗ |
| 2023-02-17 | Horn Howard | Officer | S-Sale | D | Common Stock | 2,424 | 25.29 | 61.3K | 232,960 | — | ↗ |
| 2023-02-15 | SVF Endurance (Cayman) Ltd | 10% Owner | S-Sale | D | Common Stock | 38,964 | 26.75 | 1.04M | 18,394,415 | — | ↗ |
| 2023-02-14 | SVF Endurance (Cayman) Ltd | 10% Owner | S-Sale | D | Common Stock | 38,907 | 26.81 | 1.04M | 18,433,379 | — | ↗ |
| 2023-02-13 | SVF Endurance (Cayman) Ltd | 10% Owner | S-Sale | D | Common Stock | 52,250 | 26.14 | 1.37M | 18,472,286 | — | ↗ |
| 2023-02-10 | SVF Endurance (Cayman) Ltd | 10% Owner | S-Sale | D | Common Stock | 12,813 | 25.94 | 332.3K | 18,635,744 | — | ↗ |
| 2023-02-09 | SVF Endurance (Cayman) Ltd | 10% Owner | S-Sale | D | Common Stock | 544 | 25.99 | 14.1K | 18,785,063 | — | ↗ |
| 2023-02-08 | SVF Endurance (Cayman) Ltd | 10% Owner | S-Sale | D | Common Stock | 44,498 | 28.31 | 1.26M | 18,786,907 | — | ↗ |
| 2023-02-08 | SATO VICKI L | Director | S-Sale | D | Common Stock | 17,288 | 28.35 | 490.2K | 1,345,886 | — | ↗ |
| 2023-02-07 | SVF Endurance (Cayman) Ltd | 10% Owner | S-Sale | D | Common Stock | 4,442 | 28.92 | 128.5K | 18,926,587 | — | ↗ |
| 2023-02-06 | SVF Endurance (Cayman) Ltd | 10% Owner | S-Sale | D | Common Stock | 14,752 | 30.09 | 443.9K | 18,931,029 | — | ↗ |
| 2023-02-03 | SVF Endurance (Cayman) Ltd | 10% Owner | S-Sale | D | Common Stock | 6,318 | 29.85 | 188.6K | 19,038,746 | — | ↗ |
| 2023-02-02 | SVF Endurance (Cayman) Ltd | 10% Owner | S-Sale | D | Common Stock | 86,801 | 29.70 | 2.58M | 19,045,064 | — | ↗ |
| 2023-02-01 | SVF Endurance (Cayman) Ltd | 10% Owner | S-Sale | D | Common Stock | 35,173 | 29.19 | 1.03M | 19,131,865 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-10.7K
Shares Outstanding
161.23M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Marianne De Backer, M.Sc., Ph.D., MBA President, Chief Executive Officer and Director | 950.0K | — | 2.30M | 3.51M | 1.00M | 77.1K | 7.83M | 74.09% | ↗ |
| 2 | 2025 | Mark Eisner, M.D., M.P.H Executive Vice President and Chief Medical Officer | 660.8K | 375.0K | 382.8K | 584.6K | 354.3K | 14.0K | 2.37M | 40.79% | ↗ |
| 3 | 2025 | Jason O’Byrne, MBA Executive Vice President and Chief Financial Officer | 534.4K | 150.0K | 382.8K | 584.6K | 286.1K | 14.0K | 1.95M | 49.56% | ↗ |
| 4 | 2025 | Vanina de Verneuil, J.D. Executive Vice President, General Counsel and Corporate Secretary | 506.3K | — | 335.0K | 511.5K | 329.6K | 8.4K | 1.69M | 50.06% | ↗ |
| 5 | 2024 | Marianne De Backer, M.Sc., Ph.D., MBA Chief Executive Officer and Director | 920.8K | 2.50M | 1.77M | 2.70M | 1.02M | 346.8K | 9.26M | 48.26% | ↗ |
| 6 | 2024 | Marianne De Backer, M.Sc., Ph.D., MBA President, Chief Executive Officer and Director | 920.8K | 2.50M | 1.77M | 2.70M | 1.02M | 346.8K | 9.26M | 48.26% | ↗ |
| 7 | 2024 | Mark Eisner, M.D., M.P.H Executive Vice President and Chief Medical Officer | 379.2K | 375.0K | 702.8K | 1.08M | 221.1K | 3.1K | 2.76M | 64.50% | ↗ |
| 8 | 2024 | Mark Eisner, M.D., M.P.H. Executive Vice President and Chief Medical Officer | 379.2K | 375.0K | 702.8K | 1.08M | 221.1K | 3.1K | 2.76M | 64.50% | ↗ |
| 9 | 2024 | Jason O’Byrne, MBA Executive Vice President and Chief Financial Officer | 130.5K | 150.0K | 648.0K | 991.3K | — | — | 1.92M | 85.39% | ↗ |
| 10 | 2024 | Sung Lee Former Executive Vice President and Chief Financial Officer | 184.5K | 500.0K | 404.4K | 616.6K | — | 34.0K | 1.74M | 58.70% | ↗ |
| 11 | 2024 | Vanina de Verneuil, J.D. Executive Vice President, General Counsel and Corporate Secretary | 486.7K | 300.0K | 227.5K | 346.9K | 296.4K | 12.1K | 1.67M | 34.40% | ↗ |
| 12 | 2024 | Ann (Aine) Hanly, Ph.D. Executive Vice President and Chief Technology Officer | 512.4K | — | 328.6K | 501.0K | — | 53.2K | 1.40M | 59.46% | ↗ |
| 13 | 2023 | Marianne De Backer, M.Sc., Ph.D., MBA President, Chief Executive Officer and Director | 675.0K | 2.50M | 13.42M | 21.60M | 855.4K | 437.2K | 39.49M | 88.69% | ↗ |
| 14 | 2023 | Marianne De Backer, M.Sc., Ph.D., MBA Chief Executive Officer and Director | 675.0K | 2.50M | 13.42M | 21.60M | 855.4K | 437.2K | 39.49M | 88.69% | ↗ |
| 15 | 2023 | Sung Lee Executive Vice President and Chief Financial Officer | 402.9K | — | 1.53M | 2.47M | 293.4K | 149.7K | 4.85M | 82.55% | ↗ |
| 16 | 2023 | Sung Lee Former Executive Vice President and Chief Financial Officer | 402.9K | — | 1.53M | 2.47M | 293.4K | 149.7K | 4.85M | 82.55% | ↗ |
| 17 | 2023 | Jeffrey Calcagno, M.D. Executive Vice President and Chief Business Officer | 314.4K | 400.0K | 1.41M | 2.27M | 146.1K | — | 4.54M | 81.05% | ↗ |
| 18 | 2023 | Johanna Friedl-Naderer Former Executive Vice President and Chief Operating Officer | 604.6K | — | 1.62M | 1.53M | 273.8K | 362.4K | 4.40M | 71.77% | ↗ |
| 19 | 2023 | Phillip Pang, M.D., Ph.D. Former Executive Vice President, Chief Medical Officer and Interim Head of Research | 527.0K | — | 1.62M | 1.53M | 257.8K | 13.2K | 3.95M | 79.81% | ↗ |
| 20 | 2023 | Steven Rice Former Executive Vice President and Chief Administrative Officer | 281.3K | — | 1.97M | 1.01M | — | — | 3.26M | 91.37% | ↗ |
| 21 | 2023 | Ann (Aine) Hanly, Ph.D. Executive Vice President and Chief Technology Officer | 496.0K | — | 1.01M | 1.20M | 266.9K | 133.2K | 3.11M | 71.22% | ↗ |
| 22 | 2023 | Howard Horn Former Executive Vice President and Chief Financial Officer | 159.2K | — | — | — | — | 442.1K | 601.3K | 0.00% | ↗ |
| 23 | 2023 | George Scangos, Ph.D. Former President and Chief Executive Officer | 325.0K | — | — | — | — | 13.2K | 338.2K | 0.00% | ↗ |
| 24 | 2022 | George Scangos, Ph.D. Former President and Chief Executive Officer | 638.3K | — | 2.49M | 4.04M | 295.8K | 12.2K | 7.48M | 87.35% | ↗ |
| 25 | 2022 | Johanna Friedl-Naderer Executive Vice President and Chief Operating Officer | 444.4K | 1.10M | 2.17M | 907.4K | 202.2K | 214.3K | 5.04M | 61.09% | ↗ |
| 26 | 2022 | Johanna Friedl-Naderer Former Executive Vice President and Chief Operating Officer | 444.4K | 1.10M | 2.17M | 907.4K | 202.2K | 214.3K | 5.04M | 61.09% | ↗ |
| 27 | 2022 | Phillip Pang, M.D., Ph.D. Executive Vice President, Chief Medical Officer and Interim Head of Research | 507.4K | 125.0K | 1.98M | 1.58M | 192.8K | 12.2K | 4.39M | 80.93% | ↗ |
| 28 | 2022 | Phillip Pang, M.D., Ph.D. Former Executive Vice President, Chief Medical Officer and Interim Head of Research | 507.4K | 125.0K | 1.98M | 1.58M | 192.8K | 12.2K | 4.39M | 80.93% | ↗ |
| 29 | 2022 | Herbert (Skip) Virgin, M.D., Ph.D. Former Executive Vice President, Research and Chief Scientific Officer | 437.9K | — | 2.06M | 1.73M | — | 80.4K | 4.31M | 87.97% | ↗ |
| 30 | 2022 | Ann (Aine) Hanly, Ph.D. Executive Vice President and Chief Technology Officer | 474.2K | — | 1.58M | 1.16M | 181.4K | 186.6K | 3.58M | 76.47% | ↗ |
| 31 | 2022 | Howard Horn Executive Vice President and Former Chief Financial Officer | 475.2K | — | 1.03M | 1.23M | 150.4K | 12.2K | 2.90M | 78.03% | ↗ |
| 32 | 2022 | Howard Horn Former Executive Vice President and Chief Financial Officer | 475.2K | — | 1.03M | 1.23M | 150.4K | 12.2K | 2.90M | 78.03% | ↗ |
| 33 | 2022 | Steven Rice Former Executive Vice President and Chief Administrative Officer | 485.6K | — | 589.6K | 986.7K | 184.5K | — | 2.25M | 70.17% | ↗ |
| 34 | 2021 | George Scangos, Ph.D. President and Chief Executive Officer | 575.0K | — | 7.48M | 12.13M | 487.0K | 11.6K | 20.68M | 94.81% | ↗ |
| 35 | 2021 | George Scangos, Ph.D. Former President and Chief Executive Officer | 575.0K | — | 7.48M | 12.13M | 487.0K | 11.6K | 20.68M | 94.81% | ↗ |
| 36 | 2021 | Phillip Pang, M.D., Ph.D. Former Executive Vice President, Chief Medical Officer and Interim Head of Research | 492.0K | — | 2.16M | 3.50M | 276.9K | 11.6K | 6.43M | 87.87% | ↗ |
| 37 | 2021 | Phillip Pang, M.D., Ph.D. Chief Medical Officer | 492.0K | — | 2.16M | 3.50M | 276.9K | 11.6K | 6.43M | 87.87% | ↗ |
| 38 | 2021 | Phillip Pang, M.D., Ph.D. Executive Vice President, Chief Medical Officer and Interim Head of Research | 492.0K | — | 2.16M | 3.50M | 276.9K | 11.6K | 6.43M | 87.87% | ↗ |
| 39 | 2021 | Herbert (Skip) Virgin, M.D., Ph.D. Former Executive Vice President, Research and Chief Scientific Officer | 655.6K | — | 2.02M | 3.28M | 368.9K | 95.6K | 6.42M | 82.55% | ↗ |
| 40 | 2021 | Herbert (Skip) Virgin, M.D., Ph.D. Executive Vice President, Research and Chief Scientific Officer | 655.6K | — | 2.02M | 3.28M | 368.9K | 95.6K | 6.42M | 82.55% | ↗ |
| 41 | 2021 | Howard Horn Chief Financial Officer | 461.3K | — | 1.68M | 2.73M | 259.6K | 11.6K | 5.15M | 85.78% | ↗ |
| 42 | 2021 | Howard Horn Former Executive Vice President and Chief Financial Officer | 461.3K | — | 1.68M | 2.73M | 259.6K | 11.6K | 5.15M | 85.78% | ↗ |
| 43 | 2021 | Howard Horn Executive Vice President and Former Chief Financial Officer | 461.3K | — | 1.68M | 2.73M | 259.6K | 11.6K | 5.15M | 85.78% | ↗ |
| 44 | 2021 | Ann (Aine) Hanly, Ph.D. Executive Vice President and Chief Technology Officer | 338.4K | 250.0K | 1.45M | 2.37M | 249.2K | 84.6K | 4.74M | 80.55% | ↗ |
| 45 | 2021 | Ann (Aine) Hanly, Ph.D. Chief Technology Officer | 338.4K | 250.0K | 1.45M | 2.37M | 249.2K | 84.6K | 4.74M | 80.55% | ↗ |
| 46 | 2021 | Steven Rice Former Executive Vice President and Chief Administrative Officer | 471.5K | — | 1.35M | 2.19M | 265.3K | — | 4.27M | 82.74% | ↗ |
| 47 | 2020 | Steven Rice Chief Administrative Officer | 441.7K | — | — | 1.48M | 257.0K | — | 2.17M | 67.88% | ↗ |
| 48 | 2020 | Howard Horn Executive Vice President and Former Chief Financial Officer | 444.3K | — | — | 960.2K | 226.1K | 11.4K | 1.64M | 58.48% | ↗ |
| 49 | 2020 | Howard Horn Chief Financial Officer | 444.3K | — | — | 960.2K | 226.1K | 11.4K | 1.64M | 58.48% | ↗ |
| 50 | 2020 | Herbert (Skip) Virgin, M.D., Ph.D. Former Executive Vice President, Research and Chief Scientific Officer | 636.5K | — | — | — | 374.3K | 95.4K | 1.11M | 0.00% | ↗ |
| 51 | 2020 | Herbert (Skip) Virgin, M.D., Ph.D. Executive Vice President, Research and Chief Scientific Officer | 636.5K | — | — | — | 374.3K | 95.4K | 1.11M | 0.00% | ↗ |
| 52 | 2020 | Herbert (“Skip”) Virgin, M.D., Ph.D. Executive Vice President, Research and Chief Scientific Officer | 636.5K | — | — | — | 374.3K | 95.4K | 1.11M | 0.00% | ↗ |
| 53 | 2020 | George Scangos, Ph.D. Former President and Chief Executive Officer | 544.6K | — | — | — | 438.9K | 11.4K | 994.9K | 0.00% | ↗ |
| 54 | 2020 | George Scangos, Ph.D. President and Chief Executive Officer | 544.6K | — | — | — | 438.9K | 11.4K | 994.9K | 0.00% | ↗ |
| 55 | 2020 | Michael Kamarck, Ph.D. Former Chief Technology Officer | 426.4K | — | — | — | 266.0K | 111.4K | 803.8K | 0.00% | ↗ |
| 56 | 2019 | George Scangos, Ph.D. President and Chief Executive Officer | 514.6K | — | — | 3.16M | 260.0K | 11.2K | 3.94M | 80.08% | ↗ |
| 57 | 2019 | Howard Horn Chief Financial Officer | 413.3K | — | — | 1.61M | 174.7K | 11.2K | 2.21M | 72.93% | ↗ |
| 58 | 2019 | Herbert (“Skip”) Virgin, M.D., Ph.D. Executive Vice President, Research and Chief Scientific Officer | 617.5K | — | — | 1.02M | 248.4K | 84.0K | 1.97M | 51.75% | ↗ |
| 59 | 2019 | Herbert (Skip) Virgin, M.D., Ph.D. Executive Vice President, Research and Chief Scientific Officer | 617.5K | — | — | 1.02M | 248.4K | 84.0K | 1.97M | 51.75% | ↗ |
| 60 | 2018 | Herbert (“Skip”) Virgin, M.D., Ph.D. Executive Vice President, Research and Chief Scientific Officer | 592.3K | 600.0K | — | 627.8K | 259.0K | 84.0K | 2.16M | 29.02% | ↗ |
| 61 | 2018 | Herbert (Skip) Virgin, M.D., Ph.D. Executive Vice President, Research and Chief Scientific Officer | 592.3K | 600.0K | — | 627.8K | 259.0K | 84.0K | 2.16M | 29.02% | ↗ |
| 62 | 2018 | George Scangos, Ph.D. President and Chief Executive Officer | 512.0K | — | — | — | 260.0K | 11.0K | 783.0K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Marianne De Backer | President, CEO & Director | 2M | — |
| Mark D. Eisner | Executive Vice President & Chief Medical Officer | 1M | — |
| Jason O'Byrne | Executive Vice President & Chief Financial Officer | 984.5K | male |
| Vanina De Verneuil | Executive Vice President, General Counsel & Corporate Secretary | 844.3K | female |
| Lawrence Corey | Co-Founder & Scientific Advisor | 177.7K | — |
| Louis J. Picker | Co-Founder & Scientific Advisor | 177.7K | — |
| Carolyn Wang | Senior Vice President of Corporate Communications | — | female |
| Maninder Hora | Executive Vice President & Chief Technical Operations Officer | — | — |
| Kiki Patel | Head of Investor Relations | — | — |
| Jennifer Eileen Towne | Executive Vice President & Chief Scientific Officer | — | — |
| Brent Sabatini | Senior Vice President, Principal Accounting Officer & Chief Accounting Officer | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for VIR
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
